We are live on ! Find out more
RVNC

Revance Therapeutics, Inc.
RVNC

Delisted

RVNC was delisted on the 5th of February, 2025.

Back to rankings

98 hedge funds and large institutions have $556M invested in Revance Therapeutics, Inc. in 2014 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 40 increasing their positions, 17 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,100% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 3

135% more repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 17

49% more capital invested

Capital invested by funds: $373M → $556M (+$183M)

48% more funds holding

Funds holding: 66 → 98 (+32)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
98
Holders Change
+32
Holders Change %
+48.48%
% of All Funds
2.82%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
36
Increased
40
Reduced
17
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Jennison Associates
Jennison Associates
New York
+$29.6M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$21.9M
3
ACH
ArrowMark Colorado Holdings
Colorado
+$13M
4
JP Morgan Chase
JP Morgan Chase
New York
+$12.7M
5
AllianceBernstein
AllianceBernstein
Tennessee
+$11.7M

Top Sellers

Rank Fund Capital Flow
1
VAM
Visium Asset Management
New York
-$16.8M
2
ZDA
Zweig-DiMenna Associates
New York
-$6.41M
3
Millennium Management
Millennium Management
New York
-$6.29M
4
WRF
Waddell & Reed Financial
Kansas
-$4.67M
5
PHS
PFM Health Sciences
California
-$2.66M
Name Holding Trade Value Shares
Change 		Change in
Stake
PP
51
PDT Partners
New York
$1.22M +$1.12M +35,804 New
RFC
52
Russell Frank Company
Washington
$1.09M +$1.1M +35,173 New
TCIM
53
TIAA CREF Investment Management
New York
$982K +$213K +6,794 +31%
Royal Bank of Canada
54
Royal Bank of Canada
Ontario, Canada
$888K +$468K +14,925 +133%
State of New Jersey Common Pension Fund D
55
State of New Jersey Common Pension Fund D
New Jersey
$884K +$815K +26,000 New
SI
56
Standard Investments
New York
$860K – – –
EEG
57
E.E. Geduld
$850K +$31 +1 +0%
AII
58
AGF Investments Inc
Ontario, Canada
$850K +$783K +25,000 New
BIM
59
BlackRock Investment Management
Delaware
$730K +$71.5K +2,283 +12%
GTC
60
Ghost Tree Capital
New York
$680K – – –
BAMCO Inc
61
BAMCO Inc
New York
$680K +$78.3K +2,500 +14%
PG
62
PEAK6 Group
Illinois
$646K +$595K +19,000 New
NFA
63
Nationwide Fund Advisors
Ohio
$613K +$91.3K +2,912 +19%
Charles Schwab
64
Charles Schwab
California
$525K +$483K +15,428 New
Deutsche Bank
65
Deutsche Bank
Germany
$464K +$374K +11,929 +682%
California State Teachers Retirement System (CalSTRS)
66
California State Teachers Retirement System (CalSTRS)
California
$428K – – –
Swiss National Bank
67
Swiss National Bank
Switzerland
$359K +$331K +10,550 New
TA
68
Teachers Advisors
New York
$358K -$4.89K -156 -1%
Susquehanna International Group
69
Susquehanna International Group
Pennsylvania
$351K +$324K +10,331 New
California Public Employees Retirement System
70
California Public Employees Retirement System
California
$342K +$316K +10,071 New
WMSA
71
Weiss Multi-Strategy Advisers
New York
$340K +$313K +10,000 New
PIM
72
Partner Investment Management
California
$303K -$115K -3,671 -29%
Janney Montgomery Scott
73
Janney Montgomery Scott
Pennsylvania
$281K -$6.27K -200 -2%
CS
74
Credit Suisse
Switzerland
$240K +$221K +7,066 New
RhumbLine Advisers
75
RhumbLine Advisers
Massachusetts
$213K +$197K +6,274 New
1 2
3
4 5

RVNC Hedge Fund Activity: Q2 2014 in Review

98 of the 3,481 institutional investors tracked by Wall St. Rank reported a position in Revance Therapeutics, Inc. (RVNC) for Q2 2014, worth a combined $556M — up 49% from $373M a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new RVNC positions and 3 closed out — a net gain of 33 holders — while 40 added to existing stakes and 17 trimmed.

The largest buyer was Jennison Associates, adding an estimated $29.6M. The largest seller was Visium Asset Management, cutting an estimated $16.8M.

  • 98 institutional investors held Revance Therapeutics, Inc. (RVNC) as of Q2 2014, up from 66 in Q1 2014.
  • Funds reported $556M of Revance Therapeutics, Inc. stock for Q2 2014, up 49% quarter-over-quarter.
  • 36 funds opened new Revance Therapeutics, Inc. positions in Q2 2014 and 3 closed out, a net change of +33 holders.
  • The largest Revance Therapeutics, Inc. buyer in Q2 2014 was Jennison Associates, an estimated $29.6M added.
  • The largest Revance Therapeutics, Inc. seller in Q2 2014 was Visium Asset Management, an estimated $16.8M sold.

Based on aggregated 13F filings for Q2 2014.